Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?

Moderna (MRNA) will report second-quarter earnings on Aug 1, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $124.9 million and a loss of $3.47 per share, respectively. Both metrics indicate significant declines from the year-ago quarter's levels. MRNA's loss estimates have remained consistent at $7.46 per share for 2024 and $5.29 for 2025 in the past 30 days. | --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|--- ...